Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 169-190 , June 2000

Immunomodulation therapy in colorectal carcinoma

  • D. Yip

      Affiliations

    • Department of Medical Oncology, Guy’s Hospital, St Thomas St, London, SE1 9RT
    • ,
  • A.H. Strickland

      Affiliations

    • Department of Medical Oncology, Guy’s Hospital, St Thomas St, London, SE1 9RT
    • ,
  • C.S. Karapetis

      Affiliations

    • Department of Medical Oncology, Guy’s Hospital, St Thomas St, London, SE1 9RT
    • ,
  • C.A. Hawkins

      Affiliations

    • Department of Immunology, Rayne Institute, King’s College Hospital, Denmark Hill, SE5 9NU, UK
    • ,
  • P.G. Harper

      Affiliations

    • Department of Medical Oncology, Guy’s Hospital, St Thomas St, London, SE1 9RT

References 

    REFERENCES
  1. Pisani P, Parkin DM, Bray FI, Ferlay J. Estimates of the worldwide mortality from twenty-five major cancers in 1990. Implications for prevention, and projections of future burden. Int J Cancer. 1999;83:18–29
  2. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994;86:997–1006
  3. Coleman M. Trends in cancer incidence and mortality. IARC Sci Pub. 1993;121:1
  4. Cohen A, Minsky B, Schilsky R. Cancer of the colon. In:  De Vita V,  Hellman S,  Rosenberg S editor. Cancer: Principles and Practice of Oncology, fifth edition. Philadelphia: Lippincott-Raven,; 1997;p. 1144–1197
  5. Karapetis CS, Yip D, Harper PG. The treatment of metastatic colorectal cancer. Int J Clin Pract. 1999;53:287–294
  6. Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29:545–550
  7. Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201–209
  8. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am. 1993;7:431–445
  9. Penn I. Posttransplant malignancies. Transplant Proc. 1999;31:1260
  10. Van den Eynde B, Hainaut P, Herin M. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer. 1989;44:634–640
  11. Morisaki T, Morton DL, Uchiyama A. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. Cancer Immunol Immunother. 1994;39:172–178
  12. LeMay LG, Kan-Mitchell J, Goedegebuure P, Harel W, Mitchell MS. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol Immunother. 1993;37:187–194
  13. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev. 1995;146:57–79
  14. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol. 1995;58:373–381
  15. Brunda MJ. Interleukin-12. J Leukocyte Biol. 1994;55:280–288
  16. Borish L, Rosenwasser L. Update on cytokines. J Allergy Clin Immunol. 1996;97:719–734
  17. Karr K, Ljunggren G, Piontek G, Kiessling R. Selective rejection of J-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678
  18. Jans D, Jans P, Briggs L, Sutton V, Trapani J. Nuclear transport of granzyme B (fragment-2). Dependence of perforin in vivo and cytosolic factors in vitro. J Biol Chem. 1996;271:30781–30789
  19. Trapani JA. Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. ANZ J Med. 1995;25:793–799
  20. Payne CM, Bernstein C, Bernstein H. Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Leukemia Lymphoma. 1995;19:43–93
  21. Green D. Apoptotic pathways: The roads to ruin. Cell. 1998;94:695–698
  22. Siege R, Fleisher T. The role of Fas and related death receptors in autoimmune and other disease states. J Allergy Clin Immunol. 1999;103:729–738
  23. Uzzo RG, Rayman P, Kolenko V. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 1999;5:1219–1229
  24. O’Connell J, Bennett MW, O’Sullivan GC. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol. 1999;6:457–463
  25. Pitti R, Marsters S, Lawrence D. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703
  26. Lukyx-de Bakker S, de gruijl T, Scheper R, Wagstaff J, Pinedo H. Dendritic cells: a novel therapeutic modality. Ann Oncol. 1999;10:21–27
  27. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  28. Koda K, Saito N, Takiguchi N. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg. 1997;82:190–193
  29. Chattopadhyay U. Tumour immunotherapy: developments and strategies. Immunol Today. 1999;20:481–482
  30. Murray D, Hreno A, Dutton J, Hampson L. Prognosis in colon cancer – a pathologic reassessment. Arch Surg. 1975;110:909–913
  31. Svennevig J, Lunde O, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984;49:375–377
  32. Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer. 1997;75:374–380
  33. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182:318–324
  34. Yoong K, Afford S. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol. 1999;154:593–703
  35. Venitt S. Genomic instability and cancer. In:  Yarnold J,  Stratton M,  McMillan T editor. Molecular Biology for Oncologists. London: Chapman & Hall,; 1996;p. 134–151
  36. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303–1306
  37. Jass J, Do K-A, Simms L. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 1998;42:673–679
  38. Nicholl I, Dunlop M. Molecular markers of prognosis in colorectal cancer. J Natl Cancer Inst. 1999;91:1267–1269
  39. Jarvinin H, Mecklin J, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108:1405–1411
  40. Halling K, French A, McDonnell S. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91:1295–1303
  41. Dolcetti R, Viel A, Doglioni C. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154:1805–1813
  42. Cohn M, Langman R. The protection: the unit of humoral immunity selected by evolution. Immunol Rev. 1990;115:11–18
  43. Chaux P, Moutet M, Faivre J, Martin F, Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7–1 and B7–2 costimulatory molecules of the T-cell activation. Lab Invest. 1996;74:975–983
  44. Cabrera T, Collado A, Fernandez MA. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 1998;52:114–123
  45. Diederichsen AC, Ostenhom AC, Kronborg O. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer. 1998;79:283–287
  46. Ngoi SS, Moochhala SM, Chhatwal VJ, Loh YS. The human leucocyte antigen complex: its role in colorectal cancer. Ann Acad Med Singapore. 1996;25:11–16
  47. Browning M, Petronzelli F, Bicknell D. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens. 1996;47:364–371
  48. Kaklamanis L, Townsend A, Ipatia A. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Path. 1994;145:505–509
  49. Notario A, Mazzucchelli I, Fossati G, Baldi A, Rolandi ML. Interaction in vivo between tumor cells and phagocytes. Ann NY Acad Sci. 1997;832:284–294
  50. O’Hara RJ, Greenman J, MacDonald AW. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res. 1998;4:1943–1948
  51. O’Hara RJ, Greenman J, Drew PJ. Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum. 1998;41:460–463
  52. Thorsteinsson L, O’Dowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. Apmis. 1998;106:869–878
  53. Nauts H, Fowler G, Bogatko F. A review of the influence of bacteria infections and of bacterial products (Coley’s toxins) on malignant tumors in man. Acta Med Scand. 1953;276:5–97
  54. Starnes C. Coley’s toxins in perspective. Nature. 1992;357:11–12
  55. Balkwill F, Stuart Naylor M, Malik S. Tumour necrosis factor as an anticancer agent. Eur J Cancer. 1990;26:641–644
  56. Carswell E, Old L, Kassel R. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA. 1975;72:3666–3670
  57. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast model. Int J Cancer. 1998;78:361–365
  58. Dias S, Thomas H, Balkwill F. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer. 1998;75:151–157
  59. Daver J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163–2168
  60. Leek R, Landers R, Fox S. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer. 1998;77:2246–2251
  61. Lader C, Flanagan A. Prostaglandin E2, interleukin 1-alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology. 1998;139:3157–3164
  62. Assuma R, Oates T, Cochran D, Amar S, Graves D. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol. 1998;160:403–409
  63. Amery W, Spreafico F, Rojas A, Denissen E, Chirigos M. Adjuvant treatment with levamisole in cancer: a review of experimental and clinical data. Cancer Treat Rev. 1977;4:167–194
  64. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol. 1991;9:2052–2066
  65. Rojas AF, Feierstein JN, Mickiewicz E, Glait H, Olivari AJ. Levamisole in advanced human breast cancer. Lancet. 1976;1:211–215
  66. Klefstrom P, Holsti P, Grohn P, Heinonen E, Holsti L. Levamisole in the treatment of stage II breast cancer. Five-year follow-up of a randomized double-blind study. Cancer. 1985;55:2753–2757
  67. Klefstrom P, Grohn P, Heinonen E, Holsti L, Holsti P. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. Cancer. 1987;60:936–942
  68. Klefstrom P, Nuortio L. Levamisole in the treatment of advanced breast cancer. A ten-year follow-up of a randomized study. Acta Oncol. 1991;30:347–352
  69. Klefstrom P. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer. Cancer Treat Rep. 1980;64:65–72
  70. Stephens EJ, Wood HF, Mason B. Levamisole: as adjuvant to cyclic chemotherapy in breast cancer. Rec Results Canc Res. 1978;68:139–145
  71. Hortobagyi GN, Yap HY, Blumenschein GR. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guerin. Cancer Treat Rep. 1978;62:1685–1692
  72. Kamby C, Rose C, Ejlertsen B. Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer. Eur J Cancer Clin Oncol. 1988;24:439–447
  73. Brincker H, Mouridsen HT, Anderson KW. Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. Lancet. 1980;2:824–827
  74. Quirt IC, Shelley WE, Pater JL. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991;9:729–735
  75. Lejeune F, Macher E, Kleeberg U. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761. Eur J Cancer Clin Oncol. 1988;24:S81–S90
  76. Loutfi A, Shakr A, Jerry M, Hanley J, Shibata HR. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med. 1987;10:325–328
  77. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med. 1980;303:1143–1147
  78. Davis TE, Borden EC, Wolberg WH, Crowley JJ. Levamisole and 5-fluorouracil in metastatic colorectal carcinoma (abstract). Proc Am Soc Clin Oncol. 1982;1:A396
  79. Buroker TR, Moertel CG, Fleming TR. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol. 1985;3:1624–1631
  80. Mansour EG, Cnaan A, Davis T, Hendrickson F, Schutt A. Combined modality therapy following resection of colorectal carcinoma in patients with nonmeasurable intra-abdominal metastases. An ECOG Study 3282 (abstract). Proc Am Soc Clin Oncol. 1990;9:107
  81. Bandealy MT, Gonin R, Loehrer PJ, Monaco F, Einhorn LH. Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. Clin Cancer Res. 1998;4:935–939
  82. Laurie JA, Moertel CG, Fleming TR. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447–1456
  83. Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg. 1987;74:569–572
  84. Moertel CG, Fleming TR, Macdonald JS. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  85. JAMA. 1990;264:1444–1450
  86. Moertel CG, Fleming TR, Macdonald JS. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Int Med. 1995;122:321–326
  87. Moertel CG, Fleming TR, Macdonald JS. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13:2936–2943
  88. Zoetmulder F, Taal B, Van Tinteren H. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Cancer Project (NACCP) (Abstract). Proc Am Soc Clin Oncol. 1999;18:266a
  89. Hook CC, Kimmel DW, Kvols LK. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992;31:262–267
  90. Luppi G, Zoboli A, Barbieri F. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Ann Oncol. 1996;7:412–415
  91. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993;11:2386–2390
  92. Lancet. 1995;345:939–944
  93. Wolmark N, Rockette H, Mamounas EP. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–3559
  94. O’Connell MJ, Laurie JA, Kahn M. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300
  95. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089 (abstract). Proc Am Soc Clin Oncol. 1997;16:265a
  96. Gray R, Kerr D, McConkey C, Williams N. QUASAR: a UKCCCR study of adjuvant chemotherapy (CT) for colorectal cancer (abstract). Eur J Cancer. 1999;35:S82
  97. Zalcberg J, Siderove J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol. 1996;7:41–46
  98. Kubota T, Kase S, Otani Y. Interferons alpha-2a and beta increase the antitumor activity, detected by MTT assay, of 5-fluorouracil against experimental and clinical human gastrointestinal carcinomas. Anticancer Res. 1997;17:725–728
  99. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res. 1990;50:5735–5739
  100. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 1989;163:867–874
  101. Houghton JA, Morton CL, Adkins DA, Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res. 1993;53:4243–4250
  102. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988;48:4868–4873
  103. Horowitz RW, Heerdt BG, Hu X, Schwartz EL, Wadler S. Combination therapy with 5-fluorouracil and IFN-alpha2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res. 1997;3:1317–1322
  104. Gewert DR, Shah S, Clemens MJ. Inhibition of cell division by interferons: Changes in the transport and intracellular metabolism of thymidine in human lymphoblastoid (Daudi) cells. Eur J Biochem. 1981;116:487–492
  105. Pfeffer LM, Tamm I. Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol. 1984;121:431–436
  106. Czejka MJ, Schuller J, Jager W, Fogl U, Weiss C. Influence of different doses of interferon-alpha-2b on the blood plasma levels of 5-fluorouracil. Eur J Drug Metabol Pharmacokinetics. 1993;18:247–250
  107. Danhauser LL, Freimann JH, Gilchrist TL. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol. 1993;11:751–761
  108. Grem JL, McAtee N, Murphy RF. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol. 1991;9:1811–1820
  109. Schuller J, Czejka MJ, Schernthaner G. Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. Sem Oncol. 1992;19:93–97
  110. Sparano JA, Wadler S. Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies. Adv Exp Med Biol. 1993;339:125–131
  111. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML. Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. Br J Cancer. 1994;70:724–728
  112. Pittman K, Perren T, Ward U. Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol. 1993;4:515–516
  113. Kase S, Kubota T, Watanabe M. Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics. Anticancer Res. 1995;15:153–155
  114. Wadler S, Schwartz EL, Goldman M. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989;7:1769–1775
  115. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991;9:1806–1810
  116. Kemeny N, Younes A, Seiter K. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer. 1990;66:2470–2475
  117. Pazdur R, Ajani JA, Patt YZ. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990;8:2027–2031
  118. Findlay M, Hill A, Cunningham D. Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. Ann Oncol. 1994;5:239–243
  119. Hill M, Norman A, Cunningham D. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 1995;13:2317–2323
  120. Hill M, Norman A, Cunningham D. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995;13:1297–1302
  121. Dufour P, Husseini F, Dreyfus B. 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol. 1996;7:575–579
  122. Greco FA, Figlin R, York M. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996;14:2674–2681
  123. Palmeri S, Meli M, Danova M. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol. 1998;124:191–198
  124. J Clin Oncol. 1995;13:921–928
  125. Kreuser ED, Streit M, Kuchler T. A multicenter randomized trial with the assessment of the quality of life in patients with metastatic colorectal carcinoma given either folinic acid or interferon a-2b as a modulator of 5-fluorouracil (abstract). Proc Annu Meet Am Soc Clin Oncol. 1995;14:202
  126. Kohne CH, Schoffski P, Wilke H. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 1998;16:418–426
  127. J Clin Oncol. 1992;10:896–903
  128. Houghton JA, Cheshire PJ, Morton CL, Stewart CF. Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. Clin Cancer Res. 1995;1:33–40
  129. Seymour MT, Johnson PW, Hall MR, Wrigley PF, Slevin ML. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. Br J Cancer. 1994;70:719–723
  130. Buter J, Sinnige HA, Sleijfer DT. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer. 1995;75:1072–1076
  131. Kreuser ED, Hilgenfeld RU, Matthias M. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. Semin Oncol. 1992;19:57–62
  132. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Ann Oncol. 1992;3:489–491
  133. Seymour MT, Slevin ML, Kerr DJ. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol. 1996;14:2280–2288
  134. Wolmark N, Rockette H, Fisher B. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–1887
  135. Wolmark N, Bryant J, Smith R. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998;90:1810–1816
  136. Ucer U, Bartsch H, Scheurich P, Pfizenmaier K. Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression. Int J Cancer. 1985;36:103–108
  137. Pfizenmaier K, Bartsch H, Scheurich P. Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Cancer Res. 1985;45:3503–3509
  138. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 1987;47:2563–2570
  139. Wiesenfeld M, O’Connell MJ, Wieand HS. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol. 1995;13:2324–2329
  140. O’Connell MJ, Ritts RA, Moertel CG, Schutt AJ, Sherwin SA. Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19–9. Cancer. 1989;63:1998–2004
  141. Armitage JO, Sidner RD. Antitumour effect of cimetidine [letter]. Lancet. 1979;1:882–883
  142. Kumar A. Cimetidine: an immunomodulator. Ann Pharmacother. 1990;24:289–295
  143. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994;35:1632–1636
  144. Tonnesen H, Knigge U, Bulow S. Effect of cimetidine on survival after gastric cancer. Lancet. 1988;2:990–992
  145. Matsumoto S. Cimetidine and survival with colorectal cancer [letter]. Lancet. 1995;346:115
  146. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer [letter]. Lancet. 1994;344:1768–1769
  147. Svendsen LB, Ross C, Knigge U. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum. 1995;38:514–518
  148. Kelly MD, King J, Cherian M. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer. 1999;85:1658–1663
  149. Adams WJ, Morris DL. Pilot study—cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer. 1997;80:15–21
  150. Lawson JA, Adams WJ, Morris DL. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer. 1996;73:872–876
  151. Hahm KB, Lee ED, Moon YS. Comparison of the effects of histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, on cell proliferation and immunomodulation in gastric cancer (abstract). Proc Am Soc Clin Oncol. 1996;15:220
  152. Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastro. 1995;30:265–271
  153. Hahm KB, Park IS, Kim HC. Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Int J Immunopharmacol. 1996;18:393–399
  154. Nielsen HJ, McArdle CS, Moesgaard F. The effect of ranitidine on long-term survival in primary colorectal cancer. A 40 months interim analysis. GI Cancer. 1998;2:227–233
  155. Nagata T, Miyauchi S, Kamo N. Cimetidine enhances the antiproliferative effect of 5-fluorouracil on colon carcinoma SW620. Anticancer Res. 1999;19:1153–1157
  156. Links M, Clingan PR, Phadke K. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol. 1995;21:523–525
  157. Cleveland RP, Meltzer MS, Zbar B. Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst. 1974;52:1887–1895
  158. Mikulski SM, Muggia FM. The biologic activity of MER-BCG in experimental systems and preliminary clinical studies. Cancer Treat Rev. 1977;4:103–117
  159. Zbar B. Tumor regression mediated by Mycobacterium bovis (strain BCG). NCI Monogr. 1972;35:341–344
  160. Zbar B, Bernstein ID, Bartlett GL, Hanna MG, Rapp HJ. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst. 1972;49:119–130
  161. Baldwin RW. Role of immunosurveillance against chemically induced rat tumors. Transplant Rev. 1976;28:62–74
  162. Weiss DW, Cohen D, Yron I, Stupp Y, Izak G. Proceedings: recent studies with the methanol extraction residue fraction of tubercle bacilli (MER): efficacy of distal administration against solid tumors of experimental animals, and stimulation of cellular immunologic responsiveness in cancer patients. Israel J Med Sci. 1975;11:1397
  163. Cohen D, Yron I, Grover NB, Weiss DW. Chemoimmunotherapy of syngeneic mouse mammary carcinomas employing methanol extraction residue. Ann NY Acad Sci. 1976;277:195–208
  164. Enker WE, Jacobitz JL, Craft K, Wissler RW. Surgical adjuvant immunotherapy for colorectal cancer. J Surg Oncol. 1978;10:389–397
  165. Jacobs DM, Kripke ML. Accelerated development of transplanted mammary tumors in mice pretreated with the methanol extraction residue of BCG and prevention of acceleration by concomitant specific immunization. J Natl Cancer Inst. 1974;52:219–224
  166. Haran-Ghera N, Weiss DW. Effect of treatment of C57BL-6 mice with the methanol extraction residue fraction of BCG on leukemogenesis induced by the radiation leukemia virus. J Natl Cancer Inst. 1973;50:229–234
  167. Mavligit GM, Gutterman JU, Burgess MA. Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil. Lancet. 1976;1:871–876
  168. Mavligit GM, Gutterman JU, Malahy MA. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes’ class C): prolongation of disease-free interval and survival. Cancer. 1977;40:2726–2730
  169. Higgins GA, Donaldson RC, Rogers LS, Juler GL, Keehn RJ. Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report. Cancer. 1984;54:193–198
  170. New Engl J Med. 1984;310:737–743
  171. Panettiere FJ, Goodman PJ, Costanzi JJ. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol. 1988;6:947–954
  172. Abdi EA, Hanson J, Harbora DE, Young DG, McPherson TA. Adjuvant chemoimmuno- and immunotherapy in Dukes’ stage B2 and C colorectal carcinoma: a 7-year follow-up analysis. J Surg Oncol. 1989;40:205–213
  173. Falk RE, Mann P, Langer B. Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy. Arch Surg. 1973;107:261–265
  174. Moertel CG, Ritts RE, Schutt AJ, Hahn RG. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guerin as an immunostimulant in patients with advanced cancer. Cancer Res. 1975;35:3075–3083
  175. O’Connell MJ, Moertel CG, Ritts RE, Frytak S, Reitemeier RJ. A comparative clinical and immunological assessment of methanol extraction residue of Bacillus Calmette-Guerin versus placebo in patients with advanced cancer. Cancer Res. 1979;39:3720–3724
  176. Engstrom PR, Paul AR, Catalano RB, Mastrangelo MJ, Creech RH. Fluorouracil versus fluorouracil + BCG in colorectal adenocarcinoma. In:  Terry WD,  Windhorst D editor. Immunotherapy of Cancer: Present Status of Trials in Man.. New York: Raven Press; 1978;p. 587–595
  177. Richards Fd, Muss HB, Cooper R. Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum: a prospective randomized study. Cancer. 1979;43:91–96
  178. Hersh EM, Quesada J, Murphy SG, Gutterman JU, Hutchins RD. Evaluation of therapy with methanol extraction residue of BCG (MER). Cancer Immunol Immunother. 1982;14:4–9
  179. Bedikian AY, Valdivieso M, Maroun J. Evaluation of vindesine and MER in colorectal cancer. Cancer. 1980;46:463–467
  180. Hanna MG, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer. 1978;42:2613–2625
  181. Peters LC, Brandhorst JS, Hanna MG. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res. 1979;39:1353–1360
  182. Peters LC, Hanna MG. Active specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst. 1980;64:1521–1525
  183. Hoover HC, Peters LC, Brandhorst JS, Hanna MG. Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model. J Surg Res. 1981;30:409–415
  184. Key ME, Hanna MG. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. I. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J Natl Cancer Inst. 1981;67:853–861
  185. Hanna MG, Pollack VA, Peters LC, Hoover HC. Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazid. Cancer. 1982;49:659–664
  186. Sahasrabudhe DM, deKernion JB, Pontes JE. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Mod. 1986;5:581–594
  187. Berd D, Maguire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 Patients. J Clin Oncol. 1990;8:1858–1867
  188. Hoover HC, Surdyke MG, Dangel RB, Peters LC, Hanna MG. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985;55:1236–1243
  189. Hoover HC, Brandhorst JS, Peters LC. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11:390–399
  190. Harris J, Ryan L, Adams G, Benson ADH. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes’ B and C colon cancer-EST 5283 (abstract). Proc Am Soc Clin Oncol. 1994;13:294
  191. Vermorken JB, Claessen AM, van Tinteren H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345–350
  192. Hoover H, Ransom J, Pinedo H. Meta analysis of three randomized adjuvant trials of active specific immunotherapy (ASI) of colon cancer (abstract). Proc Am Soc Clin Oncol. 1999;18:437a
  193. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980;40:717–721
  194. Fagerberg J, Frodin JE, Ragnhammar P. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?. Cancer Immunol Immunother. 1994;38:149–159
  195. Fagerberg J, Hjelm AL, Ragnhammar P. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995;55:1824–1827
  196. Johansson C, Segren S, Lindholm L. Tumour-growth suppression in nude mice by a murine monoclonal antibody: factors hampering successful therapy. Int J Cancer. 1991;48:297–304
  197. Mellstedt H, Frodin JE, Ragnhammar P. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17–1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol. 1991;30:923–931
  198. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma. 1986;5:S109–115
  199. LoBuglio AF, Saleh MN, Lee J. Phase I trial of multiple large doses of murine monoclonal antibody Co17–1a. I. Clinical Aspects. J Natl Cancer Inst. 1988;80:932–936
  200. Ragnhammar P, Frodin JE, Hjelm AL. Different dose regimens of the mouse monoclonal antibody 17–1a for therapy of patients with metastatic colorectal carcinoma. Int J Oncol. 1995;7:1049–1056
  201. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985;45:5910–5913
  202. Verrill H, Goldberg M, Rosenbaum R. Clinical trial of Wistar Institute 17–1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma. 1986;5:S175–183
  203. Frodin JE, Harmenberg U, Biberfeld P. Clinical effects of monoclonal antibodies (MAb 17–1A) in patients with metastatic colorectal carcinomas. Hybridoma. 1988;7:309–321
  204. Weiner LM, Steplewski Z, Koprowski H. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17–1A administration in patients with gastrointestinal carcinoma. Hybridoma. 1986;5:S65–77
  205. Weiner LM, Moldofsky PJ, Gatenby RA. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody Co17–1a in advanced colorectal carcinoma. Cancer Res. 1988;48:2568–2573
  206. Saleh MN, LoBuglio AF, Wheeler RH. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother. 1990;32:185–190
  207. Ragnhammar P, Masucci G, Frodin JE, Hjelm AL, Mellstedt H. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17–1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunol Immunother. 1992;35:158–164
  208. Shetye J, Ragnhammar P, Liljefors M. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17–1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1998;4:1921–1929
  209. Ragnhammar P, Fagerberg J, Frodin JE. Effect of monoclonal antibody 17–1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer. 1993;53:751–758
  210. Ragnhammar P, Magnusson I, Masucci G, Mellstedt H. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17–1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). Med Oncol Tumor Pharmacother. 1993;10:61–70
  211. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992;340:685–689
  212. Liefers GJ, Cleton-Jansen AM, van de Velde CJ. Micrometastases and survival in stage II colorectal cancer. N Eng J Med. 1998;339:223–228
  213. Pantel K, Schlimok G, Braun S. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419–1424
  214. Riethmuller G, Schneider-Gadicke E, Schlimok G. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17–1A Study Group. Lancet. 1994;343:1177–1183
  215. Riethmuller G, Holz E, Schlimok G. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788–1794
  216. Fields A, Nagy A, Schwartzberg L. Edrocolomab (Panorex, 17–1A antibody)(Edre) alone or in combination with 5-FU based chemotherapy in adjuvant treatment of stage III colon cancer: a safety review (abstract). Proc Am Soc Clin Oncol. 1999;18:435a
  217. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol. 1990;145:2758–2765
  218. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res. 1997;57:728–734
  219. Chatterjee SK, Tripathi PK, Chakraborty M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res. 1998;58:1217–1224
  220. Foon K, John W, Chakraborty M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monocloncal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res. 1997;3:1267–1276
  221. Foon KA, Yannelli J, Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res. 1999;5:225–236
  222. Foon KA, John WJ, Chakraborty M. Clinical and immune responses in surgically resected colorectal (CRC) patients treated with an anti-idiotype (Id) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil vaccine (abstract). Proc Am Soc Clin Oncol. 1998;17:435a
  223. Robins RA, Denton GW, Hardcastle JD. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res. 1991;51:5425–5429
  224. Austin E, Robins R, Baldwin R, Durrant L. Induction of delayed hypersensitivity to human tumour cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst. 1991;83:1245–1248
  225. Denton GW, Durrant LG, Hardcastle JD. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer. 1994;57:10–14
  226. Durrant LG, Buckley DJ, Spendlove I, Robins RA. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity. Hybridoma. 1997;16:23–26
  227. Durrant LG, Buckley TJ, Denton GW. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res. 1994;54:4837–4840
  228. Maxwell-Armstrong C, Durrant L, RA R. Colorectal cancer vaccine 105AD7 increases tumour infiltration of CD25-positive lymphocytes (abstract). Br J Surg. 1998;85:699
  229. Pullyblank AM, Monson JR. Monoclonal antibody treatment of colorectal cancer. Br J Surg. 1997;84:1511–1517
  230. LoBuglio A, Wheeler R, Trang J. Mouse/human chimeric monoclonal antibody in man:kinetics and immune response. Proc Natl Acad Sci USA. 1989;86:4220–4224
  231. Pardoll D. Cancer vaccines. Nature Med Vaccine Suppl. 1998;4:525–531
  232. Nawrocki S, Mackiewicz A. Genetically modified tumour vaccines—where we are today. Cancer Treat Rev. 1999;25:29–46
  233. Stewart J, Zalcberg J. Update on adjuvant treatment of colorectal cancer. Curr Opin Oncol. 1998;10:367–374
  234. de Gramont A, Figer A, Seymour M. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) (abstract). Proc Am Soc Clin Onc. 1998;17:257a
  235. Douillard Y, Cunningham D, Roth A. A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol. 1999;18:233a
  236. Chlebowski RT, Nystrom S, Reynolds R, Weiner JM, Bateman JR. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a western Cancer Study Group trial. Oncology. 1988;45:141–143
  237. Arnaud JP, Buyse M, Nordlinger B. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg. 1989;76:284–289
  238. Queisser W, Franz A, Hartung G. Prospective study of adjuvant therapy with monoclonal antibody 17–1A of Dukes’ B2/B3-colon carcinoma-interim analysis of toxicity (Abstract). Eur J Cancer. 1999;35:S70

PII: S0305-7372(99)90160-3

doi: 10.1053/ctrv.1999.0160

Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 169-190 , June 2000

Article Tools